OTCPK:CTTC

Stock Analysis Report

Executive Summary

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Calmare Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTTC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.1%

CTTC

-1.3%

US Medical Equipment

-1.1%

US Market


1 Year Return

60.2%

CTTC

19.4%

US Medical Equipment

17.8%

US Market

Return vs Industry: CTTC exceeded the US Medical Equipment industry which returned 19.4% over the past year.

Return vs Market: CTTC exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

CTTCIndustryMarket
7 Day8.1%-1.3%-1.1%
30 Day-17.1%0.02%1.5%
90 Day50.0%5.5%6.6%
1 Year60.2%60.2%20.3%19.4%20.2%17.8%
3 Year27.2%27.2%79.2%74.2%47.5%38.1%
5 Year-50.0%-50.0%114.6%92.0%71.2%52.4%

Price Volatility Vs. Market

How volatile is Calmare Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Calmare Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Calmare Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Calmare Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CTTC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Calmare Therapeutics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Calmare Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Calmare Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CTTC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Calmare Therapeutics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Calmare Therapeutics performed over the past 5 years?

11.5%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Calmare Therapeutics has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Calmare Therapeutics's financial position?


In this section we usually analyse Calmare Therapeutics's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Calmare Therapeutics has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CTTC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Calmare Therapeutics's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Calmare Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CTTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CTTC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTTC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTTC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Conrad Mir (50yo)

6.3yrs

Tenure

US$279,000

Compensation

Mr. Conrad F. Mir has been the Chief Executive Officer and President of Calmare Therapeutics Incorporated since September 27, 2013. Mr. Mir served as Interim Chief Financial Officer of Competitive Technolo ...


CEO Compensation Analysis

Compensation vs Market: Conrad's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD521.92K).

Compensation vs Earnings: Insufficient data to compare Conrad's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Conrad Mir
President6.3yrsUS$279.00kno data
Thomas Richtarich
Chief Financial Officer4.1yrsUS$113.02kno data
Donna Mays
Manager of Administrative Services3.8yrsno datano data
Stephen D'Amato
Chief Medical Officer & Member of Medical Advisory Board9.8yrsno datano data
William Lipford
Division Head of Product Sales5.5yrsno datano data

4.4yrs

Average Tenure

66yo

Average Age

Experienced Management: CTTC's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Conrad Mir
President6.3yrsUS$279.00kno data
Stephen D'Amato
Chief Medical Officer & Member of Medical Advisory Board9.8yrsno datano data
Stanley Yarbro
Independent Director7.9yrsUS$28.40kno data
Peter Brennan
Chairman of the Board7.8yrsUS$22.50kno data
Rustin Howard
Independent Director12.3yrsUS$21.00kno data
Marco Pappagallo
Member of Medical Advisory Board9.8yrsno datano data
Subash Jain
Member of Medical Advisory Board9.8yrsno datano data
Lauren Shaiova
Member of Medical Advisory Board9.8yrsno datano data
Santanu Das
Director0.6yrsno datano data

9.8yrs

Average Tenure

64yo

Average Age

Experienced Board: CTTC's board of directors are considered experienced (9.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Calmare Therapeutics Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Calmare Therapeutics Incorporated
  • Ticker: CTTC
  • Exchange: OTCPK
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.680m
  • Shares outstanding: 39.00m
  • Website: https://www.calmaretherapeutics.com

Number of Employees


Location

  • Calmare Therapeutics Incorporated
  • 1375 Kings Highway East
  • Suite 400
  • Fairfield
  • Connecticut
  • 6824
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTTCOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 1973

Biography

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 00:19
End of Day Share Price2020/02/21 00:00
Earnings2016/12/31
Annual Earnings2016/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.